FDA Outlines Process To Speed Up Rare Disease Therapy Approvals

FDA Warns: Check Can Codes

The U.S. Food and Drug Administration on Thursday introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations.

NGNE stock is showing weakness. Get the complete analysis here.